IL-7/IL-7R gene variants impact circulating IL-7/IL-7R homeostasis and ART-associated immune recovery status
Andra Ceausu(Hospital Universitari Joan XXIII de Tarragona), Anna Rull(Institut de Recerca Biomèdica Catalunya Sud), Esther Rodríguez‐Gallego(Institut de Recerca Biomèdica Catalunya Sud), Verònica Alba, Yolanda M. Pacheco(Instituto de Biomedicina de Sevilla), María Peraire(Hospital Universitario Son Espases), Carles Perpiñán, Francesc Vidal(Institut de Recerca Biomèdica Catalunya Sud), Judit Vidal‐González(Vall d'Hebron Institut de Recerca), Josep Mallolas(Hospital Clínic de Barcelona), Peré Domingo(Hospital de Sant Pau), Consuelo Viladés(Hospital Universitario Fundación Jiménez Díaz), Miguel López-Dupla, Montserrat Vargas(Hospital Universitari Joan XXIII de Tarragona), Sergi Veloso, Alfonso J. Castellano(Institut de Recerca Biomèdica Catalunya Sud), Joaquim Peraire(Instituto de Salud Carlos III), Ezequiel Ruíz-Mateos(Apple (Israel))
Cited by 9
Related Papers
Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies
|Science Translational Medicine|2017|169
Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial
|The Lancet Infectious Diseases|2015|143
Relationship between current level of immunodeficiency and non‐acquired immunodeficiency syndrome‐defining malignancies
|Cancer|2010|141
Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study
|The Lancet HIV|2021|110
Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial
|Clinical Infectious Diseases|2017|103